About ReNAgade
ReNAgade is a Healthcare company based in Cambridge (United States) founded in 2021, and was acquired by Orna in May 2024. RNA-based medicines are developed for treating multiple diseases. ReNAgade has raised $300 million across 1 funding round from investors including Orna, Turmeric Acquisition Corp and F2 Ventures. The company has 136 employees. Its chief executive, as recorded, is Amit Munshi. Its focus areas include Life Sciences, Gene Therapy, RNA and Diversified. Its legal entity is RENAGADE THERAPEUTICS MANAGEMENT, INC. Its competitors include Stoke Therapeutics, Ribometrix and Creyon Bio; 2 of its 3 listed competitors have raised funding.
Company details
ReNAgade was founded in 2021 and is based in Cambridge, United States. RNA-based medicines are developed by the company to address various diseases. Novel RNA delivery platforms are combined to enable coding, editing, and gene insertion functionalities. Operations focus on advancing therapeutic innovations within the biotechnology sector, with emphasis on precise genetic modifications for medical applications.
- Headquarters Cambridge, United States
- Employees 136
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website renagadetx.com
- Social LinkedIn X
- Acquired by Orna (May 2024)
- Legal Name Renagade Therapeutics Management, Inc.
Funding Insights of ReNAgade
ReNAgade has successfully raised a total of $300M through 1 strategic funding round. The most recent funding activity was a Series A round of $300 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $300M
- Total Rounds 1
- Last Round Series A — $300M
- First Round $300M
(May 2023)
- Investors Count 2
All 1 funding rounds of ReNAgade with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $300M | Series A | – | MPM Capital, F2 Ventures | – |
3 investors in total: 3 institutional.
Investors in ReNAgade
ReNAgade has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Orna, Turmeric Acquisition Corp and F2 Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| f2-ventures.com | ||||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Technologies for producing circular RNA therapeutics are developed. | 2020 | ornatx.com | Cambridge, United States |
Investor details for ReNAgade
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ReNAgade
5 people are tracked at ReNAgade (4 in leadership, 1 in team); the tracked headcount is 136.
| Name | Role | Group |
|---|---|---|
Amit Munshi | CEO | Leadership |
Joel Yeshman | Senior Director Finance | Leadership |
Dong Wei | Head of Bioanalysis | Leadership |
Meredith Jones | Associate Director, Legal Operations | Leadership |
Stevelyn Desire aPHR® | Senior Associate People Experience | Team |
Complete people profiles for ReNAgade
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ReNAgade
3 dated milestones of ReNAgade across 3 years, from founding to its latest funding, stage changes and deals.
- Founded ReNAgade is founded.
- Funding First funding round of $300.0M.
- Exit Acquired by Orna.
Competitors of ReNAgade
ReNAgade has 3 listed competitors in our database, 2 of them funded. They include Stoke Therapeutics, Ribometrix and Creyon Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| stoketherapeutics.com | 2014 | Bedford, United States | $130.85M | 117 | Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing | |
| ribometrix.com | 2016 | Raleigh, United States | $65.3M | 26 | RNA-targeted drug discovery platform using three-dimensional structural analysis is provided. | |
| creyonbio.com | 2019 | San Diego, United States | Oligonucleotide-based drug development platform is provided using AI models. |
Detailed competitors of ReNAgade
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as ReNAgade (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Renagade
Complete news archive for ReNAgade
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReNAgade
ReNAgade was founded in 2021 and raised its 1st funding round 2 years after it was founded.
ReNAgade is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Amit Munshi is the CEO of ReNAgade, as recorded in our data.
ReNAgade is a funded company, having raised a total of $300M across 1 funding round to date. The company's 1st funding round was a Series A of $300M, raised on May 2023.
ReNAgade has 136 employees.
ReNAgade was founded in 2021 and is based in Cambridge, United States. RNA-based medicines are developed by the company to address various diseases. Novel RNA delivery platforms are combined to enable coding, editing, and gene insertion functionalities. Operations focus on advancing therapeutic innovations within the biotechnology sector, with emphasis on precise genetic modifications for medical applications.
ReNAgade's top competitors include Stoke Therapeutics, Ribometrix and Creyon Bio.
ReNAgade has 3 investors. Key investors include Orna, Turmeric Acquisition Corp, and F2 Ventures.
ReNAgade operates through Renagade Therapeutics Management, Inc..
Yes. ReNAgade was acquired by Orna in May 2024.